These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3481692)

  • 1. Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Chan MK; Chau PY; Chan WW
    Clin Nephrol; 1987 Dec; 28(6):277-80. PubMed ID: 3481692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral treatment of peritonitis in CAPD patients with ofloxacin.
    Chan MK; Chau PY; Chan WW
    Nephrol Dial Transplant; 1988; 3(2):194-7. PubMed ID: 3140086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients?
    Gucek A; Bren AF; Lindic J; Hergouth V; Mlinsek D
    Adv Perit Dial; 1994; 10():144-6. PubMed ID: 7999813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics].
    Denis F; Mounier M; Lagarde C; Benevent D
    Pathol Biol (Paris); 1987 May; 35(5):652-5. PubMed ID: 3302879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of the number of peritonitis episodes on peritoneal membrane function].
    Jovanović D; Nesić V; Dimitrijević Z
    Srp Arh Celok Lek; 1999; 127(1-2):28-31. PubMed ID: 10377837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis.
    Yoshimoto K; Saima S; Echizen H; Nakamura Y; Ishizaki T
    Clin Nephrol; 1993 Aug; 40(2):114-7. PubMed ID: 8222367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis.
    Passadakis P; Oreopoulos D
    Adv Perit Dial; 2001; 17():180-90. PubMed ID: 11510271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics of vancomycin in chronic renal failure patients in continuous ambulatory peritoneal dialysis (CAPD) after intra-abdominal administration].
    Mounier M; Benevent D; Denis F
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):542-4. PubMed ID: 3911152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of IgG, C3 and transferrin with opsonising and bacteriostatic activity of peritoneal fluid from CAPD patients and the incidence of peritonitis.
    McGregor SJ; Brock JH; Briggs JD; Junor BJ
    Nephrol Dial Transplant; 1987; 2(6):551-6. PubMed ID: 3126457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multiple-dose kinetics of ofloxacin in patients on continuous ambulatory peritoneal dialysis (CAPD).
    Passlick J; Wonner R; Keller E; Essers L; Grabensee B
    Perit Dial Int; 1989; 9(4):267-72. PubMed ID: 2488379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transperitoneal resorption of cefotiam in CAPD patients with and without peritonitis].
    Thomae U; Koblinger S
    Med Klin (Munich); 1994 Sep; 89(9):464-8. PubMed ID: 7968880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
    Choi KC; Jeong TK; Lee SC; Kim SW; Kim NH; Lee KY
    Adv Perit Dial; 1998; 14():173-9. PubMed ID: 10649719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pharmacokinetics of intraperitoneal ofloxacin in patients on continuous ambulatory peritoneal dialysis.
    Cheng IK; Chau PY; Kumana CR; Chan CY; Kou M; Siu LK
    Perit Dial Int; 1993; 13 Suppl 2():S383-5. PubMed ID: 8399617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis.
    Tomino Y; Fukui M; Hamada C; Inoue S; Osada S
    Arzneimittelforschung; 1998 Aug; 48(8):862-7. PubMed ID: 9748717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling peritoneal dialysis.
    Sisterhen LL; Stowe CD; Farrar HC; Blaszak CK; Blaszak RT
    Am J Kidney Dis; 2006 Mar; 47(3):503-8. PubMed ID: 16490630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glucose concentration on peritoneal inflammatory cytokines in continuous ambulatory peritoneal dialysis patients.
    Sayarlioglu H; Topal C; Sayarlioglu M; Dulger H; Dogan E; Erkoc R
    Mediators Inflamm; 2004 Apr; 13(2):119-21. PubMed ID: 15203553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal comparison of intermittent versus continuous ambulatory peritoneal dialysis, in the same patients.
    Madden MA; Zimmerman SW; Simpson DP
    Clin Nephrol; 1981 Dec; 16(6):293-9. PubMed ID: 6797767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis.
    Halstenson CE; Blevins RB; Salem NG; Matzke GR
    Clin Nephrol; 1984 Nov; 22(5):239-43. PubMed ID: 6335067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.